Six-month evaluation of novel bioabsorbable scaffolds composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles in porcine coronary arteries

Abstract

Objective

Using coronary angiography and intravascular ultrasound methods to evaluate the performance of the novel fully bioabsorbable scaffold (NFBS) composed of poly-L-lactic acid/amorphous calcium phosphate (PLLA/ACP) at six-month follow-up by comparing with PLLA scaffolds

Methods

Twelve PLLA/ACP scaffolds and 12 PLLA scaffolds were implanted into the coronary arteries of 12 miniature pigs. Quantitative coronary angiography (QCA) was used to measure the reference vessel diameter (RVD), mean lumen diameter (MLD) and late lumen loss (LLL). According to IVUS images, we calculated the strut malapposition rate (SMR) at post implantation, strut overlap rate (SOR), reference vessel area (RVA), mean stent area (MSA), mean lumen area (MLA) and luminal patency rate (LPR) at six-month follow-up. The radial strength of the scaffold was evaluated using a catheter tensile testing machine.

Results

QCA results indicated that, at six month, MLD of PLLA/ACP scaffolds was greater than those of PLLA scaffolds (2.47 ± 0.22 mm vs. 2.08 ± 0.25 mm, P < 0.05); LLL of PLLA/ACP scaffolds was less than those of PLLA scaffolds (0.42 ± 0.20 mm vs. 0.75 ± 0.22 mm, P < 0.05). IVUS results showed the SMR and SOR were all significantly less with the PLLA/ACP scaffolds than the PLLA scaffolds (5.84% ± 3.56% vs. 17.72% ± 4.86%, P < 0.05) (6.17% ± 4.63% vs. 17.65% ± 4.29%, P < 0.05). MSA, MLA and LPR of the PLLA/ACP scaffolds were all greater than those of PLLA scaffolds (6.35 ± 0.45 mm² vs. 5.35 ± 0.51 mm², P < 0.05) (4.76 ± 0.46 mm² vs. 3.77 ± 0.46 mm², P < 0.05) (78.01% ± 12.29% vs. 61.69% ± 9.76%, P < 0.05). Radial strength of PLLA/ACP scaffold at six month was greater than that of PLLA scaffold (76.33 ± 3.14 N vs. 67.67 ± 3.63 N).

Conclusion

The NFBS had less stent recoil, better lumen patency rate and greater radial strength than PLLA scaffolds. The results suggest the NFBS scaffolds can maintain the structural strength and functional performance, which are effective for up to six months when implanted in porcine coronary arteries.

Keywords

Biomaterials fully bioabsorbable scaffold poly-L-lactic acid amorphous calcium phosphate coronary heart disease miniature pigs

Get full access to this article

View all access options for this article.

References

Yamawaki

Shimokawa

Kozai

et al . Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998; 32: 780–786.

Onuma

Serruys

PW.

Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?

Circulation 2011; 123: 779–797.

Zhang

Bourantas

Farooq

et al . Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices 2013; 6: 37–48.

Moore

Soares

Rajagopal

Biodegradable stents: biomechanical modeling challenges and opportunities. Cardiovasc Eng Tech 2010; 1: 52.

van der Giessen

Lincoff

Schwartz

et al . Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690–1697.

Commandeur

van Beusekom

van der Giessen

WJ.

Polymers, drug release, and drug-eluting stents. J Interv Cardiol 2006; 19: 500–506.

Borzacchiello

Gloria

Mayol

et al . Natural/synthetic porous scaffold designs and properties for fibro-cartilaginous tissue engineering. J Bioactive Compat Polym 2011; 26: 437–451.

Patricio

Domingos

Gloria

et al . Fabrication and characterisation of PCL and PCL/PLA scaffolds for tissue engineering. Rapid Prototyping J 2014; 20: 145–156.

Lan

Lyu

Xiao

et al . Novel biodegradable drug-eluting stent composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles demonstrates improved structural and functional performance for coronary artery disease. J Biomed Nanotechnol 2014; 10: 1194–1204.

10.

Combes

Rey

Amorphous calcium phosphates: synthesis, properties and uses in biomaterials. Acta Biomater 2010; 6: 3362–3378.

11.

Dorozhkin

SV.

Amorphous calcium (ortho)phosphates. Acta Biomater 2010; 6: 4457–4475.

12.

Zheng

Wang

Lan

et al . Improved biocompatibility of poly(lactic-co-glycolic acid) orv and poly-L-lactic acid blended with nanoparticulate amorphous calcium phosphate in vascular stent applications. J Biomed Nanotechnol 2014; 10: 900–910.

13.

Saber-Samandari

Gross

KA.

Amorphous calcium phosphate offers improved crack resistance: a design feature from nature?

Acta Biomater 2011; 7: 4235–4241.

14.

Tamai

Myoui

Hirao

et al . A new biotechnology for articular cartilage repair: subchondral implantation of a composite of interconnected porous hydroxyapatite, synthetic polymer (PLA-PEG), and bone morphogenetic protein-2 (rhBMP-2). Osteoarthr Cartil 2005; 13: 405–417.

15.

Muller

Hofmann

et al . Cellulose-based scaffold materials for cartilage tissue engineering. Biomaterials 2006; 27: 3955–3963.

16.

Gao

Weng

Cheng

et al . Preparation, characterization and cytocompatibility of porous ACP/PLLA composites. J Biomed Mater Res A 2006; 79: 193–200.

17.

Huang

Yang

Yan

et al . Osteochondral repair using the combination of fibroblast growth factor and amorphous calcium phosphate/poly(L-lactic acid) hybrid materials. Biomaterials 2007; 28: 3091–3100.

18.

Feng

Xiao

Lan

et al . 12-Month coronary angiography, intravascular ultrasound and histology evaluation of a novel fully bioabsorbable poly-L-lactic acid/amorphous calcium phosphate scaffolds in porcine coronary arteries. J Biomed Nanotechnol 2016; 12: 743–752.

19.

Gu D, Feng G, Kang G, et al. Improved biocompatibility of novel biodegradable scaffold composed of poly-Llactic acid and amorphous calcium phosphate nanoparticles in porcine coronary artery. J Nanomater 2016; 4: 1–8.